Android app Apple app link

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

By Yahoo! Finance   |   3 weeks ago
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca's Phase 3 trial on Enhertu for HER2-positive metastatic breast cancer showed significant PFS improvement with Enhertu-pertuzumab combo compared to standard care THP. The trial continues with promising interim OS results.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.